283 related articles for article (PubMed ID: 27015255)
21. Pharmacotherapeutic strategies for castrate-resistant prostate cancer.
Moussa M; Papatsoris A; Abou Chakra M; Sryropoulou D; Dellis A
Expert Opin Pharmacother; 2020 Aug; 21(12):1431-1448. PubMed ID: 32469248
[TBL] [Abstract][Full Text] [Related]
22. Independent association between time to prostate-specific antigen (PSA) nadir and PSA progression-free survival in patients with docetaxel-naïve, metastatic castration-resistant prostate cancer receiving abiraterone acetate, but not enzalutamide.
Miyake H; Hara T; Tamura K; Sugiyama T; Furuse H; Ozono S; Fujisawa M
Urol Oncol; 2017 Jun; 35(6):432-437. PubMed ID: 28188090
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases.
Wen L; Yao J; Valderrama A
J Manag Care Spec Pharm; 2019 Mar; 25(3-b Suppl):S1-S11. PubMed ID: 30827188
[TBL] [Abstract][Full Text] [Related]
24. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
[TBL] [Abstract][Full Text] [Related]
26. New therapeutic options in metastatic castration-resistant prostate cancer: Can cost-effectiveness analysis help in treatment decisions?
Wilson L; Tang J; Zhong L; Balani G; Gipson G; Xiang P; Yu D; Srinivas S
J Oncol Pharm Pract; 2014 Dec; 20(6):417-25. PubMed ID: 24243919
[TBL] [Abstract][Full Text] [Related]
27. Treatment of Metastatic, Castration-resistant, Docetaxel-resistant Prostate Cancer: A Systematic Review of Literature With a Network Meta-analysis of Randomized Clinical Trials.
Tassinari D; Cherubini C; Roudnas B; Tamburini E; Drudi F; Bianchi E; Fantini M; Montanari F; Sartori S
Rev Recent Clin Trials; 2018; 13(3):226-237. PubMed ID: 29623850
[TBL] [Abstract][Full Text] [Related]
28. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
de Bono JS; Smith MR; Saad F; Rathkopf DE; Mulders PFA; Small EJ; Shore ND; Fizazi K; De Porre P; Kheoh T; Li J; Todd MB; Ryan CJ; Flaig TW
Eur Urol; 2017 Apr; 71(4):656-664. PubMed ID: 27402060
[TBL] [Abstract][Full Text] [Related]
29. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U
JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559
[TBL] [Abstract][Full Text] [Related]
30. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
Davies RS; Smith C; Lester JF
Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
[TBL] [Abstract][Full Text] [Related]
31. Impact of prior androgen receptor-axis-targeted agents on the clinical activity of subsequent docetaxel in patients with metastatic castration-resistant prostate cancer: comparative assessment between abiraterone acetate and enzalutamide.
Miyake H; Matsushita Y; Tamura K; Motoyama D; Ito T; Sugiyama T; Otsuka A
Med Oncol; 2017 Nov; 34(12):200. PubMed ID: 29164346
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic options for first-line metastatic castration-resistant prostate cancer: Suggestions for clinical practise in the CHAARTED and LATITUDE era.
Tucci M; Caffo O; Buttigliero C; Cavaliere C; D'aniello C; Di Maio M; Kinspergher S; Maines F; Rizzo M; Rossetti S; Veccia A; Scagliotti GV; Facchini G
Cancer Treat Rev; 2019 Mar; 74():35-42. PubMed ID: 30738364
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran.
Goudarzi Z; Lotfi F; Najafpour Z; Hafezi A; Zakaria MA; Keshavarz K
BMC Urol; 2024 Feb; 24(1):45. PubMed ID: 38378521
[TBL] [Abstract][Full Text] [Related]
34. Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
Peters ML; de Meijer C; Wyndaele D; Noordzij W; Leliveld-Kors AM; van den Bosch J; van den Berg PH; Baka A; Gaultney JG
Appl Health Econ Health Policy; 2018 Feb; 16(1):133-143. PubMed ID: 28866822
[TBL] [Abstract][Full Text] [Related]
35. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
de Bono JS; Chowdhury S; Feyerabend S; Elliott T; Grande E; Melhem-Bertrandt A; Baron B; Hirmand M; Werbrouck P; Fizazi K
Eur Urol; 2018 Jul; 74(1):37-45. PubMed ID: 28844372
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analyses and cost analyses in castration-resistant prostate cancer: A systematic review.
Grochtdreis T; König HH; Dobruschkin A; von Amsberg G; Dams J
PLoS One; 2018; 13(12):e0208063. PubMed ID: 30517165
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer.
Gong CL; Hay JW
J Natl Compr Canc Netw; 2014 Oct; 12(10):1417-25. PubMed ID: 25313181
[TBL] [Abstract][Full Text] [Related]
38. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Ramaekers BLT; Riemsma R; Tomini F; van Asselt T; Deshpande S; Duffy S; Armstrong N; Severens JL; Kleijnen J; Joore MA
Pharmacoeconomics; 2017 Feb; 35(2):191-202. PubMed ID: 27566699
[TBL] [Abstract][Full Text] [Related]
39. Safety and Efficacy of First-Line Treatments for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Indirect Comparison.
Zheng H; Chen J; Qiu W; Lin S; Chen Y; Liang G; Fang Y
Biomed Res Int; 2017; 2017():3941217. PubMed ID: 29951524
[TBL] [Abstract][Full Text] [Related]
40. Sequencing of agents in castration-resistant prostate cancer.
Lorente D; Mateo J; Perez-Lopez R; de Bono JS; Attard G
Lancet Oncol; 2015 Jun; 16(6):e279-92. PubMed ID: 26065613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]